Hubbry Logo
SIRVASIRVAMain
Open search
SIRVA
Community hub
SIRVA
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
SIRVA
SIRVA
SIRVA
View on Wikipedia
from Wikipedia

SIRVA, Inc. (formerly Allied Worldwide), based in Oakbrook Terrace, Illinois, is a privately owned American moving industry holding company which resulted from the merger of Allied Van Lines with North American Van Lines. The corporate name was coined from the Latin word servire, "to serve."

Key Information

The company was formed in 1999 when private equity company Clayton, Dubilier & Rice merged its Allied and North American businesses. In 2002, it traded on the New York Stock Exchange under its new SIRVA name with the ticker symbol of "SIR."

"In 2024 SIRVA has a downgraded credit rating from S&P global, with a very negative outlook regarding its financial stability and long term debt. Source: https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3164764"

History

[edit]

In 1998, Clayton, Dubilier & Rice formed SIRVA to acquire North American Van Lines, Inc., one of the largest U.S. moving services companies, from Norfolk Southern Corporation. In 1999, the firm bought the Allied and Pickfords businesses from NFC plc and was renamed Allied Worldwide. Several acquisitions followed in 2002 and 2003. Seeing a trend of corporate customers outsourcing all aspects of employee relocation, including household goods moves, the firm acquired the relocation services business of Cooperative Resource Services (CRS) in May 2002, and later that year bought Rowan Simmons in the UK. In 2003, it opened an office in Hong Kong and acquired PRS Europe of Belgium. SIRVA is unusual in that it includes both relocation and moving companies under its umbrella; its main competitors are one or the other.[1]

On February 11, 2002 Allied Worldwide was renamed to SIRVA, Inc. The company announced its initial public offering, and its common shares became listed on the New York Stock Exchange under the symbol "SIR". During its first year as a public company in 2003, it reported operations in 40 countries with over 7,700 employees. Its network of service providers operated in 175 countries.[citation needed] It had revenue of $2.35 billion and assets of $1.55 billion. It provided services to 38% of the Fortune 500 companies, among 2,500 corporate clients worldwide. It had 760 moving agents; these agents had a fleet size of 7,800 vehicles.[2] During February 2008, the company entered bankruptcy and re-organized, emerging in May 2008 as a private company.[3][4]

During 2011, the firm acquired Peninsular Properties in Hong Kong, a real estate company providing a full range of destination services. During 2012, it acquired Concept Mobility Services, a São Paulo, Brazil-based relocation and move management company. During 2013, it opened an office in Doha, Qatar under the brand Allied Pickfords.[5]

SIRVA brands

[edit]
Main articles: Allied Van Lines and North American Van Lines
Allied and North American Van Lines

SIRVA, Inc. is a combination of businesses with a long history. Allied Van Lines (AVL) was founded in 1928 and North American Van Lines (NAVL) was founded in 1933. Beginning in late 1964, NAVL created its STI (Specialized Transportation Inc.)|High Value Products Division (HVPD), which later was bought out from SIRVA and taken private as an independent company named Specialized Transportation Inc.[citation needed]

On November 21, 1999, Clayton, Dubilier & Rice also completed their acquisition of Allied Van Lines and merged it with North American Van Lines to create 'Allied Worldwide, although each former company maintained its own profile names. Valued at approximately US$450 million in the merger, the combined entity became the world's largest relocation and van line logistics company.

Other events

On October 11, 2004, a group of 43 North American Van Lines' agents, named the Specialized Transportation Agent Group Inc., purchased NAVL's High Value Products Division from SIRVA. The buyers renamed the new company Specialized Transportation Inc. (STI).[citation needed] On August 1, 2005, SIRVA sold its warehouse operation business to Lake Capital, a banking company. The business was named NAL Worldwide, a limited liability company in order to be a familiar sound to previous customers and anyone familiar with the old North American Logistics. NAL is chiefly involved in warehousing operations and logistics.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

SIRVA

View on Grokipedia
from Grokipedia
Shoulder Injury Related to Vaccine Administration (SIRVA) is a rare but recognized complication arising from improper of a into the region, leading to persistent pain and dysfunction. It typically manifests as shoulder pain and limited occurring within 48 hours after intended for the , often resulting from the needle entering structures such as the , , or . The primary cause of SIRVA is suboptimal injection technique, such as placing the needle too high on the arm or using excessive force, which can inadvertently deposit the into sensitive tissues rather than the intended muscle. This condition has been formally acknowledged in the U.S. since 2017, allowing for claims related to injuries temporally linked to . Common associated diagnoses include subacromial-subdeltoid , , and adhesive capsulitis, with symptoms frequently appearing immediately or within 24 hours in over half of cases. Although rare, with incidence rates estimated at 1 to 2 cases per million doses for , SIRVA reports increased during mass campaigns, such as for , predominantly affecting women and involving like or tetanus-diphtheria-pertussis. Treatment for SIRVA focuses on conservative management, beginning with rest, ice, and anti-inflammatory medications to alleviate acute symptoms, followed by to restore mobility. In cases of persistent inflammation, injections into the affected or joint provide relief for many patients, while severe or refractory instances may require surgical intervention such as . Prevention remains paramount and is achieved through proper practices, including accurate anatomic landmarking to target the thickest part of the , appropriate needle length selection based on patient age and body habitus, and ensuring the arm is relaxed during administration. Early recognition and referral to specialists, such as orthopedists, are recommended to mitigate long-term , as untreated SIRVA can lead to lasting months to years.

Definition and Background

Definition

Shoulder injury related to vaccine administration (SIRVA) is a recognized adverse event following immunization characterized by persistent shoulder pain and limited range of motion that develops within 48 hours after an intramuscular vaccine injection in the deltoid region, resulting from inadvertent injection into the glenohumeral joint or other improper needle placement. This condition arises from mechanical injury to shoulder structures such as the bursa, tendons, or ligaments, often due to the vaccine being administered too high or too deeply in the deltoid muscle. SIRVA is described as a rare complication of vaccination, with incidence estimates varying across studies but generally reported around 1-2 cases per million doses administered based on surveillance data from large-scale immunization programs. Unlike the common transient soreness that resolves within 24-48 hours after vaccination, SIRVA represents a structural injury leading to prolonged dysfunction unresponsive to standard analgesics. It has been associated with various vaccines, including influenza and COVID-19 formulations.

Epidemiology

Shoulder injury related to vaccine administration (SIRVA) is a rare following , with estimated incidence rates ranging from 1 to 2 cases per million doses of vaccine administered in general vaccination programs. During large-scale vaccination efforts, such as those for , reporting has been elevated; for instance, analysis of European EudraVigilance data from 2020 to 2022 indicated an incidence of approximately 3.7 cases per 100,000 vaccinations, equivalent to 37 per million doses. These figures underscore SIRVA's low overall prevalence, though underreporting likely affects true estimates, particularly in settings without systematic adverse event monitoring. Demographically, SIRVA predominantly affects adults in the 40- to 60-year age range, with a mean age of around 52 years among reported cases. Women are disproportionately impacted, comprising 70% to 76% of cases and yielding a female-to-male of approximately 2:1 to 3:1. Risk appears higher among individuals with smaller body habitus, lower (BMI), or reduced bulk, potentially due to shallower allowing inadvertent deeper injection. Trends in SIRVA recognition have accelerated since , coinciding with enhanced global vaccine safety surveillance and the of initial case series that formalized the condition. Reporting spiked during annual campaigns and dramatically during immunization drives; U.S. (VAERS) data documented over 1,000 possible SIRVA reports from to 2016 for vaccines alone, with an additional surge exceeding 300 cases in the first seven months of 2021 amid widespread . Globally, SIRVA cases are more frequently documented in high-income countries equipped with robust systems, including the , , and , where passive reporting mechanisms and no-fault compensation programs facilitate detection and attribution. In contrast, underreporting prevails in low- and middle-income regions due to limited , though the condition's occurrence is presumed similar worldwide given universal practices.

Causes and Pathophysiology

The primary mechanism of shoulder injury related to vaccine administration (SIRVA) involves inadvertent injection of the into the , glenohumeral joint, or surrounding soft tissues rather than the intended intramuscular site in the . This misplacement exposes sensitive structures to vaccine components, triggering a localized inflammatory response primarily driven by immune reactivity to antigens or adjuvants within the formulation. For instance, adjuvants such as aluminum salts or other can provoke an exaggerated immune cascade in these confined spaces, leading to rapid onset of pain and dysfunction. Following the injection, a pathophysiological cascade ensues, beginning with acute inflammation that manifests as in the subacromial space, of the tendons, or within the glenohumeral joint. This inflammatory process is mediated by the release of pro-inflammatory cytokines in response to the foreign material, causing , synovial irritation, and potential mechanical impingement. If unresolved, the acute phase may progress to chronic changes, including , formation, and intra-articular adhesions that restrict shoulder mobility. Common injection errors contributing to SIRVA include placement too high on the , often in the proximal deltoid just 2-3 cm below or above the , which risks breaching the due to its superficial location extending 3-6 cm distal to the . Use of needles longer than appropriate for the patient's deltoid thickness (typically exceeding 2-3 cm penetration) can risk penetrating the or humeral head, while improper needle angulation—deviating from the recommended 90-degree insertion—may direct the laterally into periarticular tissues. The typical volume of intramuscular vaccines administered, ranging from 0.5 to 1 mL, plays a role in amplifying intra-articular and irritation when misdirected, as even small volumes can overwhelm the limited capacity of the or space. Larger volumes, if used, further exacerbate this by increasing hydrostatic distension and prolonging exposure of tissues to inflammatory agents.

Anatomical Factors

The shoulder joint's complex anatomy plays a critical role in the risk of shoulder injury related to vaccine administration (SIRVA) during deltoid intramuscular injections, as inadvertent needle placement can affect sensitive structures beneath the . The itself serves as the primary target for intramuscular delivery, forming a triangular layer over the glenohumeral joint that originates from the lateral , , and spine of the , and inserts into the of the . Beneath this muscle lie vulnerable structures, including the subacromial-subdeltoid —a synovial sac that reduces friction between the process and the tendons—as well as the tendons (supraspinatus, infraspinatus, teres minor, and subscapularis) and the glenohumeral , which encapsulates the humeral head within the . Injection into these areas, rather than the muscle bulk, can lead to localized , with the being particularly susceptible due to its superficial position relative to the deltoid. A key vulnerability zone in deltoid injections is the region immediately superior to the safe injection site, where the process serves as an anatomical . The recommended "safe zone" for adults is approximately 2 to 3 fingerbreadths (or 5 to 7.5 cm) below the inferior edge of the , targeting the thickest portion of the to avoid superficial or deep structures. Injections placed higher than this zone—such as within 1 to 2 cm of the —heighten the risk of penetrating the subacromial-subdeltoid bursa or even the glenohumeral joint, as the bursa extends superiorly from about 3 to 6 cm below the , and the lies adjacent. This proximity underscores how minor deviations in site selection can result in non-muscular deposition of vaccine contents, exacerbating injury potential. Individual anatomical variations significantly influence SIRVA susceptibility, particularly in populations with smaller shoulder dimensions. Women often exhibit a shorter distance from the to the (approximately 5.72 ± 0.75 cm) compared to men (6.57 ± 0.83 cm), alongside reduced bulk and thinner , increasing the likelihood of erroneous needle placement relative to bony landmarks. Similarly, individuals with low (BMI) or smaller overall stature—such as those with limited or thin habitus—face elevated risks due to shallower muscle depth and compressed safe zones, where scapular positioning (e.g., protraction or elevation) can further alter the effective depth of the deltoid relative to the skin surface. These variations highlight the need for personalized assessment, as standard landmarks may not account for such differences. Needle length selection must align with anatomical depth to prevent inadvertent deep penetration in susceptible individuals. Standard 1-inch (25 ) needles, commonly used for deltoid injections, may prove excessively long for patients with low BMI (e.g., <25 kg/), potentially traversing the deltoid entirely and impinging on the subdeltoid bursa, , or humeral head, with studies indicating subacromial penetration risks in approximately 52% of cases using standard 1-inch (25 ) needles. Shorter needles, such as 5/8-inch (16 ) or 1-inch options tailored to BMI, are recommended for those with minimal subcutaneous fat to ensure intramuscular delivery without excess depth. This mismatch between generic needle sizes and individual contributes to SIRVA by promoting unintended contact with deeper structures.

Clinical Features

Symptoms and Signs

Shoulder injury related to vaccine administration (SIRVA) typically manifests with acute onset of symptoms shortly following intramuscular in the deltoid region, often due to improper injection technique. Pain usually begins within 48 hours of , distinguishing it from expected post-injection soreness that resolves quickly. This pain is characterized as severe and persistent, frequently rated above 7 on the Visual Analog Scale (VAS), with some cases reporting initial scores of 10/10, and it often peaks within 24 to 48 hours before continuing unabated. Without intervention, symptoms commonly persist for more than 6 months, and in many instances extend to years, affecting daily function. The primary symptoms include intense pain that is unrelenting and poorly responsive to over-the-counter analgesics, accompanied by significant restrictions in both active and passive . Patients often exhibit limited abduction and flexion, for example, less than 90 degrees in abduction, with some cases restricted to as little as 45 degrees. in arm elevation is also common, contributing to functional impairment such as difficulty raising the arm overhead. Associated physical signs encompass tenderness over the deltoid and regions upon , along with localized swelling due to or . may be noted during shoulder movement in some instances, reflecting underlying or . to the neck or arm can occasionally occur, exacerbating discomfort. The condition progresses from an acute inflammatory phase, marked by sharp pain and swelling, to a subacute stage characterized by increasing and reduced mobility if left unresolved, often resembling adhesive capsulitis.

Differential Diagnosis

The differential diagnosis of shoulder injury related to vaccine administration (SIRVA) includes several conditions that can present with acute shoulder pain and limited range of motion, necessitating careful evaluation to distinguish them based on , clinical features, and targeted investigations. Common musculoskeletal mimics encompass tears, which typically arise from acute trauma or degenerative changes without a recent , often confirmed by magnetic resonance imaging (MRI) showing tendon disruption unrelated to injection site inflammation. Adhesive capsulitis, or frozen shoulder, usually develops gradually over weeks to months with progressive stiffness and minimal initial acute pain, contrasting with SIRVA's rapid onset, and lacks the direct temporal association with immunization. Bursitis from overuse or repetitive strain presents with insidious symptoms and no injection-related trigger, differentiating it through absence of the characteristic post-vaccination timeline. Autoimmune or inflammatory reactions must also be considered, such as Parsonage-Turner syndrome (neuralgic amyotrophy), which involves inflammation leading to severe pain followed by rapid and , often requiring electrodiagnostic studies to identify neuropathic changes not seen in SIRVA. Vaccine-induced , though rare, manifests as diffuse proximal muscle involvement with elevated levels and systemic fatigue, unlike the localized bursal or tendinous inflammation in SIRVA. Infectious etiologies represent critical differentials, including , characterized by fever, , , and elevated white blood cell count, typically requiring aspiration for confirmation of pathogens, which is absent in SIRVA. Post-injection abscesses present with localized fluctuance, warmth, and purulent drainage at the site, often visualized on or MRI, and demand antimicrobial therapy or drainage, setting them apart from the sterile inflammatory process of SIRVA. Key differentiation clues for SIRVA include its close temporal proximity to , with pain onset within 48 hours (and up to 2 months in some definitions), the lack of systemic symptoms like fever or , and a favorable response to conservative measures such as medications and , often resolving within 4-6 weeks. In contrast, mimics like s or neuralgic amyotrophy may persist or worsen without specific interventions targeting or neuropathy.

Diagnosis

Clinical Evaluation

Clinical evaluation of suspected shoulder injury related to vaccine administration (SIRVA) begins with a detailed history to establish the temporal and contextual relationship between vaccination and symptom onset. Key elements include the exact date and site of administration, details about the vaccinator (e.g., professional training or technique used), and any pre-existing shoulder conditions or injuries that could confound the . Patients should also report their occupation and typical activity level, as these factors influence functional impairment and guide assessment of . Common symptoms, such as acute pain and restricted shoulder movement, are typically reported within 48 hours of . The physical examination focuses on objective assessment of shoulder function to identify localized . is evaluated using a , with active forward flexion often limited to less than 120° in affected individuals (normal: 150°–180°), alongside restrictions in abduction, internal, and external rotation. Strength testing includes maneuvers like the empty can test to assess supraspinatus integrity, where weakness or pain on resisted abduction indicates rotator cuff involvement. reveals focal tenderness over the deltoid, , or , potentially with signs of local such as swelling. Red flags warranting urgent referral include neurological deficits such as , numbness, or weakness radiating beyond the , which may suggest nerve involvement. Systemic signs of illness, like fever or widespread , could indicate secondary infection or inflammatory response requiring prompt evaluation. Diagnostic criteria for SIRVA, adapted from established guidelines, require persistent pain and limited onset within 48 hours post-vaccination, absence of pre-existing , and exclusion of alternative causes through clinical assessment. These criteria emphasize the rapid temporal association and functional limitation to differentiate SIRVA from unrelated conditions.

Imaging and Laboratory Tests

Diagnosis of shoulder injury related to vaccine administration (SIRVA) often relies on imaging modalities to visualize involvement and exclude alternative pathologies. (MRI) is the preferred imaging modality for evaluating involvement in SIRVA, demonstrating key features such as subacromial-subdeltoid , , rotator cuff or , and occasionally bone erosions or osteonecrosis. provides a complementary, dynamic assessment of bursal fluid accumulation and inflammation in the subacromial space, offering real-time evaluation and guiding potential aspirations. Plain radiography () is typically employed as an initial imaging step to rule out fractures, , or osseous abnormalities, though it has limited utility for evaluation in SIRVA. In cases where MRI is contraindicated or unavailable, computed (CT) may assess bony structures and joint integrity, but it is less sensitive for details compared to MRI. Laboratory tests play a supportive role in SIRVA diagnosis, primarily to quantify and exclude infectious complications. Inflammatory markers such as (ESR) and (CRP) are often elevated in acute presentations, reflecting the underlying or . If systemic symptoms like fever are present, count (WBC) and blood cultures should be obtained to rule out or .

Management

Initial Treatment

The initial management of shoulder injury related to vaccine administration (SIRVA) emphasizes conservative, non-invasive strategies to reduce pain, inflammation, and functional limitations in the early stages. First-line treatments typically involve rest, possibly with a sling if needed to support the affected and minimize aggravation from daily activities. Alternating applications of (to reduce acute swelling) and (to promote circulation after the initial phase) are recommended several times daily, alongside over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, provided there are no contraindications like gastrointestinal issues or renal impairment. Physical therapy plays a central role in early recovery, beginning gently as tolerated post-onset to prevent while avoiding further irritation. Initial exercises focus on passive restoration, such as pendulum swings—where the patient leans forward and allows the arm to dangle and swing freely in small circles—to maintain mobility without active resistance. Progression to active-assisted exercises occurs as tolerated, guided by a therapist to prioritize pain-free movement and stabilization. If symptoms persist without substantial improvement after 2 weeks of conservative measures, intra-bursal injections under guidance are often employed to target directly in the subacromial-subdeltoid . A typical regimen involves a such as triamcinolone or dexamethasone mixed with a local anesthetic, administered to confirm accurate placement and provide immediate relief. Ongoing monitoring is essential, with clinical follow-up scheduled at 2-4 weeks to assess progress, adjust therapies, and evaluate for diagnostic confirmation via if needed. With these initial approaches, many patients experience improvement, though full resolution occurs in approximately 25-30% of cases and may take months to years; more recent data from vaccination cases suggest higher rates of symptom resolution (around 50-80%) with conservative management.

Advanced Interventions

Advanced interventions for shoulder injury related to vaccine administration (SIRVA) are reserved for cases that remain refractory to conservative management, typically after 3-6 months of persistent pain, limited , or significant functional impairment despite treatments such as , nonsteroidal anti-inflammatory drugs, and local corticosteroid injections. These indications often include MRI evidence of ongoing , such as or , and severe disability impacting daily activities. Surgical options focus on addressing structural damage and removing inflamed or reactive tissues. Arthroscopic bursectomy, involving subacromial decompression and debridement of the bursa, is commonly performed to excise inflamed bursal tissue and any foreign body reactions, as demonstrated in case series where irrigation and biopsy confirmed bacterial involvement like Cutibacterium acnes. Capsular release may be combined with bursectomy to alleviate adhesions in cases of secondary adhesive capsulitis. If imaging reveals a rotator cuff tear—sometimes exacerbated by the initial injury—arthroscopic repair is indicated to restore tendon integrity and prevent further deterioration. These procedures are minimally invasive, allowing for outpatient recovery in select patients. Pharmacologic escalation may precede or complement in cases. A short course of oral corticosteroids, such as prednisolone at 30 mg daily for 5-7 days, can reduce when local injections prove insufficient, with reported benefits in severe presentations. Biologic agents like (PRP) injections have been explored for their potential to promote tissue healing in chronic shoulder conditions, including rotator cuff pathology associated with SIRVA; however, evidence specific to SIRVA remains limited, with mixed results in broader shoulder studies showing short-term pain relief but no consistent long-term superiority over corticosteroids. Outcomes following advanced interventions vary but generally show substantial improvement in function for most . In a case series of SIRVA treated with arthroscopic , single assessment numeric evaluation (SANE) scores improved to 75-95 at 7-30 months postoperatively, indicating high satisfaction and restored use, though one experienced residual weakness. Surgical risks include recurrence, progression to frozen , or incomplete resolution, particularly if underlying is not addressed with adjunctive antibiotics. Rehabilitation typically spans 3-6 months, emphasizing progressive strengthening and mobility exercises to optimize recovery and prevent stiffness. Overall, while up to 31% of SIRVA cases may require surgical intervention, complete resolution is achieved in fewer than one-third, underscoring the need for individualized management.

Prevention

Proper Administration Techniques

Proper administration of intramuscular (IM) injections in the requires precise site selection to avoid structures such as the and , which can lead to shoulder injury related to vaccine administration (SIRVA) if the injection is placed too high or shallow. Although the is the standard site for adult vaccine administration due to accessibility, alternative sites such as the ventrogluteal in the may be considered when the deltoid is unsuitable, as they avoid structures altogether. For deltoid injections, the "safe zone" is located 2-5 cm below the process, at the of the deltoid muscle's vertical length, ensuring placement in the thickest central portion and avoiding the upper third where bursal involvement is more likely. The patient's arm should be relaxed at their side or slightly abducted to facilitate accurate landmarking and muscle access. Needle selection is critical for reaching the muscle without excessive depth that could penetrate unintended tissues. A 22-25 gauge needle is recommended for most adults to balance ease of insertion and patient comfort. For adults, a 5/8-inch (16 mm) length may be used for those weighing less than 60 kg when the skin is stretched taut; a 1-inch (25 mm) length is recommended for those weighing 60-90 kg (women) or 60-118 kg (men), with longer needles (1.5 inches) for heavier individuals to ensure intramuscular deposition. The needle must be inserted at a 90-degree angle to the skin surface after stretching the skin laterally, promoting direct muscle penetration. Key procedural steps include palpating anatomical landmarks—the and axillary fold—to confirm the site. The should be injected steadily, with rates such as 0.1 mL per second recommended in some guidelines to balance minimization and tissue trauma. After injection, apply gentle pressure to the site with a gauze pad for , but avoid vigorous , as it may displace the into or cause irritation. Recipients should be advised to move the arm periodically in the hours following administration to facilitate dispersal within the muscle and reduce localized soreness.

Vaccinator Training

Standardized training programs for vaccinators are essential to minimize the risk of shoulder injury related to vaccine administration (SIRVA) by ensuring proper injection techniques. The Centers for Disease Control and Prevention (CDC) recommends comprehensive, competency-based training for all healthcare personnel involved in vaccine administration, covering policies, best practices, and site selection to avoid improper needle placement. Similarly, the World Health Organization (WHO) provides guidelines through its Best Practices for Injections and Related Procedures Toolkit, which emphasizes training on safe injection practices, including infection control and anatomical considerations to prevent adverse events like SIRVA. These programs equip providers with the knowledge to identify key anatomical landmarks, such as the acromion process, for accurate deltoid injections. Core components of effective vaccinator training include anatomy review, hands-on simulation, and competency assessments. Training modules typically incorporate detailed instruction on shoulder anatomy to guide needle insertion, often using visual aids and diagrams. Hands-on practice with mannequins allows providers to simulate intramuscular injections, reinforcing correct angles and depths to avoid bursal or joint involvement. Competency checklists, provided by organizations like the CDC, evaluate skills such as site preparation, needle selection, and post-injection monitoring, ensuring providers meet standardized criteria before independent practice. Training frequency is structured to maintain proficiency, with annual certification required for providers in programs like the CDC's Vaccines for Children (VFC), involving updates on evolving guidelines and error prevention. During mass immunization campaigns, such as those for or , intensified training sessions are prioritized to address high-volume administration and reinforce SIRVA avoidance protocols. Barriers to effective often stem from gaps among providers, such as between nurses, who may have more routine exposure, and pharmacists, who report inadequate hands-on preparation for injections. Solutions include targeted e-learning modules and visual aids; for instance, the CDC's You Call the Shots interactive web-based courses offer accessible, self-paced simulations to bridge these disparities. Studies demonstrate the impact of such , with one showing a nearly 72% reduction in overall administration errors following and mentoring interventions. Integration into medical and curricula further sustains these benefits, as seen in programs like the Teaching Immunization for (TIME) modules, which embed vaccinator competencies into core coursework for future providers.

History and Associated Vaccines

Historical Recognition

Early reports of shoulder pain following vaccine administration appeared in the medical literature during the 1990s, primarily documented through the U.S. Vaccine Adverse Event Reporting System (VAERS), which was established in 1990 to monitor potential vaccine side effects. These isolated cases described persistent shoulder dysfunction and pain after immunization, often attributed to improper injection techniques, though the condition lacked a standardized name or formal recognition at the time. The term "Shoulder Injury Related to Vaccine Administration" (SIRVA) was first coined in 2010 by Atanasoff et al. in a case series published in , detailing 13 patients with acute shoulder pain and limited occurring within 48 hours of vaccination. In 2017, the U.S. (HRSA) formally recognized SIRVA as a compensable injury under the by adding it to the Vaccine Injury Table, enabling affected individuals to seek compensation without proving causation. This milestone marked the transition from anecdotal reports to a defined medicolegal entity. Research on SIRVA evolved from individual case reports to more structured analyses, with a notable surge in studies following the widespread rollout of vaccines in 2020, which highlighted the condition's during mass immunization campaigns. Systematic reviews, such as the 2022 analysis by MacMahon et al., synthesized data from 42 studies involving over 2,300 cases, confirming a causal link between improper deltoid injections and shoulder injuries like , , and adhesive capsulitis. These reviews emphasized the role of injection site and technique in causality, shifting focus toward prevention. In 2020, the Department of Health and Human Services (HHS) proposed removing SIRVA from the Vaccine Injury Table, but this rule was rescinded in March 2021, maintaining its status as a compensable injury. Regulatory responses have included ongoing monitoring through VAERS, with the (VICP) seeing SIRVA claims increase significantly after 2010, from 10 claims in 2011 to 711 in 2019. In response to rising cases, particularly during the , the Advisory Committee on Immunization Practices (ACIP) issued guidance in 2021 reinforcing proper injection techniques, such as selecting the correct needle length and site to avoid intra-articular or subacromial delivery, as part of broader vaccine administration safety protocols.

Implicated Vaccines

Shoulder injury related to vaccine administration (SIRVA) has been most frequently associated with vaccines, which account for the majority of reported cases due to their widespread annual use. In a of 45 cases, vaccines were implicated in 62% of instances, followed by pneumococcal vaccines at 13%. Tetanus-diphtheria-pertussis (Tdap) and vaccines have also been linked to SIRVA in clinical reports, though less commonly than or pneumococcal types. During the vaccination campaign, SIRVA reports surged in 2021, with mRNA-based vaccines such as Pfizer-BioNTech and comprising the bulk of cases in the (VAERS). Analysis of VAERS data from January to September 2021 identified 305 SIRVA cases following vaccination, including 152 (49.8%) after , 123 (40.3%) after Pfizer-BioNTech, and only 30 (9.9%) after the adenovirus vector Janssen vaccine. This pattern reflects the higher administration volume of mRNA vaccines compared to Janssen during that period. No definitive causal link has been established by specific brand, as SIRVA primarily arises from improper injection technique rather than composition, with similar delivery volumes across brands contributing to overall incidence. Reporting biases influence SIRVA data, with higher notification rates observed for vaccines administered in public settings like pharmacies, particularly seasonal shots. Centers for Disease Control and Prevention analysis of federal claims indicated that most SIRVA injuries occurred at pharmacies or retail stores, likely due to greater public access and reporting awareness in these venues compared to clinical settings.

References

  1. https://www.federalregister.gov/documents/2017/01/19/2017-00701/national-vaccine-injury-compensation-program-revisions-to-the-vaccine-injury-table
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC8797178/
  3. https://stacks.cdc.gov/view/cdc/119221
  4. https://www.sciencedirect.com/science/article/pii/S2667276622000828
  5. https://immunisationhandbook.health.gov.au/resources/publications/avoiding-shoulder-injury-related-to-vaccine-administration
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9174179/
  7. https://radsource.us/vaccine-related-shoulder-injury/
  8. https://pubmed.ncbi.nlm.nih.gov/34009164/
  9. https://dig.pharmacy.uic.edu/faqs/2025-2/february-2025-faqs/what-are-the-recommendations-to-identify-and-manage-shoulder-injury-related-to-vaccine-administration-sirva/
  10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576975/
  11. https://immunisationhandbook.health.gov.au/sites/default/files/2021-07/Publication-Avoiding-shoulder-injury-related-to-vaccine-administration.pdf
  12. https://nap.nationalacademies.org/read/27746/chapter/12
  13. https://www.sciencedirect.com/science/article/pii/S0264410X25001896
  14. https://www.mdpi.com/2379-139X/11/5/53
  15. https://www.sciencedirect.com/science/article/pii/S0264410X23009751
  16. https://www.sciencedirect.com/science/article/abs/pii/S0264410X22003371
  17. https://stacks.cdc.gov/view/cdc/119221/cdc_119221_DS1.pdf
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6707642/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC9576975/
  20. https://www.researchgate.net/publication/363878488_Shoulder_injury_related_to_vaccine_administration_SIRVA_What_do_we_know_about_its_incidence_and_impact
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC8934720/
  22. https://www.sciencedirect.com/science/article/pii/S2666639123000305
  23. https://www.mdpi.com/2076-393X/11/7/1164
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC10754365/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC10757374/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC9284989/
  27. https://www.nature.com/articles/s41541-025-01279-7
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6347325/
  29. https://journals.sagepub.com/doi/full/10.1177/2165079919875161
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC6344966/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC8900789/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC12115978/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC10069733/
  34. https://www.cmaj.ca/content/194/2/e46
  35. https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2321672
  36. https://www.ramoslaw.com/navigating-the-legal-and-medical-landscape-of-sirva-what-you-need-to-know-about-shoulder-injury-related-to-vaccine-administration/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC10936633/
  38. https://www.sciencedirect.com/science/article/pii/S2773157X22000509
  39. https://rcastoragev2.blob.core.windows.net/7190e1bb0c77b255bfdc11e40bbf283d/PMC8314792.pdf
  40. https://www.racgp.org.au/afp/2016/may/don-t-aim-too-high-avoiding-shoulder-injury-relate
  41. https://www.nysora.com/pain-management/ultrasound-guided-shoulder-joint-and-bursa-injections/
  42. https://www.foadorthopaedic.com/wp-content/uploads/2017/01/Frozen-Shoulder-After-Flu-Vaccine.pdf
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC9983336/
  44. https://www.sciencedirect.com/science/article/abs/pii/S0264410X22007502
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC10426568/
  46. https://www.researchgate.net/publication/349444709_Arthroscopic_Surgical_Management_of_Shoulder_Secondary_to_Shoulder_injury_related_to_vaccine_administration_SIRVA_A_Case_Report
  47. https://pubmed.ncbi.nlm.nih.gov/34185028/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC9027408/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC10155124/
  50. https://jsesreviewsreportstech.org/article/S2666-6391%2823%2900030-5/fulltext
  51. https://journals.sagepub.com/doi/10.1177/2165079919875161
  52. https://www.cdc.gov/vaccines/hcp/admin/downloads/IM-injection-adult.pdf
  53. https://www.ncbi.nlm.nih.gov/books/NBK556121/
  54. https://www.publichealthontario.ca/-/media/Documents/nCoV/Vaccines/2021/07/immunization-technique-intramuscular-injections-deltoid.pdf
  55. https://www.cdc.gov/vaccines/hcp/admin/administer-vaccines.html
  56. https://www.cdc.gov/vaccines/hcp/imz-best-practices/vaccine-administration.html
  57. https://pharmacy.uconn.edu/course/immunizationquickrefresher/
  58. https://www.unitypoint.org/news-and-articles/6-ways-to-prevent-arm-soreness-after-a-vaccine
  59. https://www.cdc.gov/vaccines/hcp/administration/index.html
  60. https://www.who.int/publications-detail-redirect/who-best-practices-for-injections-and-related-procedures-toolkit
  61. https://www.ochsnerjournal.org/content/22/3/261
  62. https://www.cdc.gov/vaccines/hcp/administration/resources.html
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC9980645/
  64. https://www.cdc.gov/vaccines-for-children/hcp/information-for-providers/index.html
  65. https://www.who.int/teams/immunization-vaccines-and-biologicals/essential-programme-on-immunization/implementation/immunization-campaigns
  66. https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1893
  67. https://www.cdc.gov/immunization-training/hcp/you-call-the-shots/index.html
  68. https://www.doctorsofnursingpractice.org/wp-content/uploads/project_form/complete_170420113518.pdf
  69. https://www.aptrweb.org/page/time
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC8249056/
  71. https://pubmed.ncbi.nlm.nih.gov/20955829/
  72. https://pubmed.ncbi.nlm.nih.gov/35323136/
  73. https://www.federalregister.gov/documents/2021/03/17/2021-05486/national-vaccine-injury-compensation-program-revisions-to-the-vaccine-injury-table
  74. https://stacks.cdc.gov/view/cdc/57623/cdc_57623_DS1.pdf
  75. https://immunizationinfo.com/fluad-lawsuit/
  76. https://www.nbcwashington.com/news/local/half-of-all-new-federal-vaccine-injury-cases-allege-shots-given-incorrectly/53621/
Add your contribution
Related Hubs
User Avatar
No comments yet.